What are the causes, recommended treatment, and key investigations for cellulitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cellulitis: Causes, Treatment, and Key Investigations

Causes and Microbiology

Beta-hemolytic streptococci (especially Streptococcus pyogenes) and methicillin-sensitive Staphylococcus aureus (MSSA) cause the vast majority of cellulitis cases. 1, 2 In the 15% of cases where organisms are identified, these two pathogens account for nearly all culturable infections. 2 The majority of cellulitis cases (approximately 85%) remain nonculturable, making empiric therapy essential. 2

Portal of Entry and Risk Factors

  • Preceding skin trauma (minor abrasion, insect bite, injection site) serves as the portal of entry in most cases. 1
  • Predisposing conditions include venous insufficiency, lymphedema, chronic edema, obesity, eczema, and tinea pedis with toe web abnormalities. 1
  • Diabetes mellitus increases risk and requires special consideration for polymicrobial coverage. 1
  • Immunocompromise or neutropenia elevates risk for severe infection. 1

First-Line Treatment for Uncomplicated Cellulitis

Beta-lactam monotherapy is the standard of care for typical nonpurulent cellulitis, achieving 96% clinical success. 1, 2 MRSA is an uncommon cause of typical cellulitis even in high-prevalence settings, making routine MRSA coverage unnecessary. 1, 3

Oral Antibiotic Options (Choose One)

  • Cephalexin 500 mg orally every 6 hours for 5 days 1, 3
  • Dicloxacillin 250–500 mg orally every 6 hours for 5 days 1, 3
  • Amoxicillin 500 mg orally three times daily for 5 days 1
  • Penicillin V 250–500 mg orally four times daily for 5 days 1

Intravenous Options for Hospitalized Patients

  • Cefazolin 1–2 g IV every 8 hours (preferred IV beta-lactam) 1, 3
  • Nafcillin 2 g IV every 6 hours (alternative) 1, 3
  • Oxacillin 2 g IV every 6 hours (alternative) 1

Treatment Duration

Treat for exactly 5 days if clinical improvement occurs (resolution of warmth/tenderness, improving erythema, no fever); extend only if symptoms have not improved. 1, 3 High-quality randomized controlled trial evidence demonstrates that 5-day courses are as effective as 10-day courses for uncomplicated cellulitis. 1 Traditional 7–14-day regimens are no longer necessary. 1


When to Add MRSA Coverage

Add MRSA-active antibiotics ONLY when specific risk factors are present. 1, 3, 2 Do not routinely add MRSA coverage for typical cellulitis, as this represents overtreatment in approximately 96% of cases. 1

MRSA Risk Factors (Any One Triggers Coverage)

  • Penetrating trauma or injection drug use 1, 3
  • Purulent drainage or exudate (visible at infection site) 1, 3
  • Known MRSA colonization or prior MRSA infection 1, 3
  • Systemic inflammatory response syndrome (SIRS): fever >38°C, heart rate >90 bpm, respiratory rate >24 breaths/min 1, 3
  • Failure to respond to beta-lactam therapy after 48–72 hours 1, 3

MRSA-Active Regimens (When Indicated)

For purulent cellulitis (monotherapy options):

  • Clindamycin 300–450 mg orally every 6 hours for 5 days (provides single-agent coverage for both streptococci and MRSA; use only if local MRSA clindamycin resistance <10%) 1, 3

For nonpurulent cellulitis requiring MRSA coverage (combination therapy mandatory):

  • Trimethoprim-sulfamethoxazole (TMP-SMX) 1–2 double-strength tablets twice daily PLUS cephalexin 500 mg every 6 hours for 5 days 1, 3
  • Doxycycline 100 mg orally twice daily PLUS cephalexin 500 mg every 6 hours for 5 days 1, 3

Never use doxycycline or TMP-SMX as monotherapy for typical cellulitis—they lack reliable activity against beta-hemolytic streptococci. 1, 3


Severe Cellulitis Requiring Hospitalization

Hospitalization Criteria (Any One Mandates Admission)

  • Systemic inflammatory response syndrome (SIRS): fever, tachycardia, hypotension, altered mental status 1, 3
  • Signs of necrotizing infection: severe pain out of proportion to exam, skin anesthesia, rapid progression, "wooden-hard" tissue, gas in tissue, bullous changes 1
  • Severe immunocompromise or neutropenia 1, 3
  • Failure of outpatient treatment after 24–48 hours 1

IV Antibiotic Regimens for Severe Infection

For severe cellulitis with systemic toxicity or suspected necrotizing fasciitis:

  • Vancomycin 15–20 mg/kg IV every 8–12 hours PLUS piperacillin-tazobactam 3.375–4.5 g IV every 6 hours 1, 3
  • Alternative combinations: vancomycin PLUS meropenem 1 g IV every 8 hours, OR vancomycin PLUS ceftriaxone 2 g IV daily and metronidazole 500 mg IV every 8 hours 1

For complicated cellulitis without systemic toxicity (MRSA coverage needed):

  • Vancomycin 15–20 mg/kg IV every 8–12 hours (first-line, A-I evidence) 1, 3
  • Linezolid 600 mg IV twice daily (A-I evidence) 1, 3
  • Daptomycin 4 mg/kg IV once daily (A-I evidence) 1, 3
  • Clindamycin 600 mg IV every 8 hours (A-III evidence; only if local MRSA resistance <10%) 1, 3

Treatment duration for complicated infections is 7–14 days, individualized based on clinical response. 1


Key Investigations

When Laboratory Testing Is NOT Needed

For uncomplicated cellulitis without systemic signs, no laboratory studies are required. 3 Blood cultures are positive in only approximately 5% of typical cases and are therefore unnecessary. 1, 3

When to Obtain Laboratory Studies

Order the following ONLY when systemic toxicity is present (fever >38°C, tachycardia, hypotension, altered mental status): 3

  • Blood cultures with susceptibility testing 3
  • Complete blood count with differential 3
  • Serum creatinine, bicarbonate, creatine phosphokinase (CPK), and C-reactive protein (CRP) 3

Laboratory Abnormalities Indicating Higher Risk

Consider hospitalization if any of the following are present: 3

  • Hypotension or elevated serum creatinine 3
  • Low serum bicarbonate 3
  • CPK ≥2–3× upper limit of normal 3
  • Marked left-shift on white-cell differential 3
  • CRP >13 mg/L 3

Tissue Cultures and Biopsies

Gram stain and culture of needle-aspiration or punch-biopsy specimens are indicated ONLY in patients with: 3

  • The laboratory abnormalities listed above 3
  • Severe systemic features, malignancy, neutropenia, or unusual predisposing factors 1

Imaging Studies

Imaging is reserved for specific clinical scenarios: 1

  • Plain radiographs or MRI when osteomyelitis is suspected (probing to bone, chronic non-healing wounds) 1
  • Ultrasound to assess for abscess when clinical uncertainty exists (any fluctuance requires incision and drainage) 1
  • MRI for suspected necrotizing fasciitis, deep abscess, or osteomyelitis 1

Do not delay antibiotics to obtain imaging when clinical presentation is straightforward. 1


Essential Adjunctive Measures

  • Elevate the affected extremity above heart level for at least 30 minutes three times daily to promote gravity drainage of edema and inflammatory substances. 1, 3
  • Examine interdigital toe spaces for tinea pedis, fissuring, scaling, or maceration—treating these eradicates colonization and reduces recurrent infection risk. 1, 3
  • Address predisposing conditions: venous insufficiency, lymphedema, chronic edema, obesity, eczema. 1, 3
  • Consider systemic corticosteroids (prednisone 40 mg daily for 7 days) in nondiabetic adults, though evidence is limited. 1, 3 Avoid corticosteroids in diabetic patients. 1

Prevention of Recurrent Cellulitis

Annual recurrence rates are 8–20% in patients with previous cellulitis. 1 For patients with 3–4 episodes per year despite treating predisposing factors, consider prophylactic antibiotics: 1

  • Penicillin V 250 mg orally twice daily for 4–52 weeks 1
  • Erythromycin 250 mg orally twice daily for 4–52 weeks 1
  • Intramuscular benzathine penicillin every 2–4 weeks 1

Common Pitfalls to Avoid

  • Do not add MRSA coverage reflexively for typical nonpurulent cellulitis without specific risk factors—this overtreats 96% of cases and promotes resistance. 1, 3
  • Do not use doxycycline or TMP-SMX as monotherapy for typical cellulitis—they lack reliable streptococcal coverage. 1, 3
  • Do not automatically extend therapy to 7–10 days—extend only if warmth, tenderness, or erythema have not improved after 5 days. 1, 3
  • Do not delay surgical consultation when signs of necrotizing infection (severe pain out of proportion, skin anesthesia, rapid progression, "wooden-hard" tissue) are present. 1, 3
  • Do not obtain blood cultures or extensive laboratory testing for typical uncomplicated cellulitis—this represents unnecessary resource utilization. 3
  • Do not treat simple abscesses with antibiotics alone—incision and drainage is the primary treatment. 1, 3

Monitoring and Follow-Up

Reassess patients within 24–48 hours to verify clinical response. 1, 3 Treatment failure rates of approximately 21% have been reported with some oral regimens. 1 If no improvement after 48–72 hours of appropriate therapy, consider: 1

  • Resistant organisms (MRSA) 1
  • Undrained abscess 1
  • Deeper infection (necrotizing fasciitis, septic arthritis, osteomyelitis) 1
  • Alternative diagnoses (deep vein thrombosis, venous stasis dermatitis, contact dermatitis) 1, 4

References

Guideline

Management of Cellulitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Cellulitis: A Review.

JAMA, 2016

Guideline

Management of Cellulitis of the Ear

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Cellulitis: diagnosis and management.

Dermatologic therapy, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.